News

New Brain Tumor Clinical Trials: April – October 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting since our last report for patients with a primary brain tumor. Follow the hyperlink for […] November 7, 2024

Updated: Exciting News for Patients with Grade 2 Oligodendroglioma and Astrocytoma UPDATED (August 6, 2024): The U.S. Food and Drug Administration (FDA) has approved vorasidenib (brand name: Voranigo) for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. This is […] August 6, 2024

New Brain Tumor Clinical Trials: January – March 2024 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients. This report provides a summary of the studies that have recently opened or started recruiting (January 1, 2024 – April 9, 2024) for patients with a primary brain tumor*. Follow […] April 12, 2024

From College Challenges to Clinical Trials: A Story of Resilience Little did Julia V. know that her troubling symptoms as an undergraduate were a precursor to a life-altering brain tumor diagnosis in college and a profound understanding of the patient experience as a health care professional years later. During her junior year at Washington University in St. Louis, Missouri, majoring in microbiology and anthropology, Julia […] August 25, 2023

New Brain Tumor Clinical Trials: July- December 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for patients with a primary brain tumor*. Follow the hyperlink above to learn more about […] January 20, 2023